35
Participants
Start Date
March 20, 2017
Primary Completion Date
December 14, 2021
Study Completion Date
March 3, 2022
Pembrolizumab
"Pembrolizumab 200mg IV every 21 days~\+~Physician's choice chemotherapy with one of the following every 21 days:~* Docetaxel 75mg/m2 IV~* Pemetrexed 500mg/m2 IV (non-squamous only)~* Gemcitabine 1000mg/m2 IV on days 1 and 8"
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
University of Iowa Hospital Clinics, Iowa City
University of Wisconsin, Madison
University of Minnesota Medcical Center, Minneapolis
University of Illinois Cancer Center, Chicago
Merck Sharp & Dohme LLC
INDUSTRY
Big Ten Cancer Research Consortium
OTHER
Greg Durm, MD
OTHER